Navigation Links
Mylan Announces Completion of Transdermal Patch Facility Expansion Project in St. Albans, Vt.
Date:9/4/2013

ST. ALBANS, Vt., Sept. 4, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced the completion of an 85,000 square foot, three-story expansion project at its transdermal patch facility, operated by Mylan Technologies Inc. (MTI), in St. Albans, Vt. Through Mylan's investment, including funding for expanded research and development (R&D) capabilities and additional manufacturing and laboratory space, the company is in the process of adding more than 160 new positions to its St. Albans-based workforce. MTI is a proven leader in transdermal drug delivery systems – patches that deliver medication through the skin – and related technologies.

In conjunction with the expansion project, Mylan today hosted a ribbon-cutting ceremony to commemorate the occasion. Vermont Governor Peter Shumlin as well as a number of local officials, community members and employees, attended the event.

Mylan CEO Heather Bresch said: "Mylan's investment in the ongoing growth of our transdermal franchise demonstrates our continued commitment to and confidence in our ability to provide complex generic and interchangeable products and innovative delivery alternatives, such as transdermals. Through this expansion, MTI will continue to play a critical role in the expansion and diversification of Mylan's global product portfolio, especially when it comes to difficult-to-develop and –manufacture products. I would like to thank Governor Shumlin as well as the city of St. Albans for their ongoing support of this project. Importantly, I would also like to recognize Mylan's more than 590 employees in Vermont for their hard work and dedication to our continued success."

The 14-month expansion project has increased MTI's total operating space to more than 391,000 square feet. Since becoming a part of the Mylan manufacturing network more than 20 years ago, MTI has developed a number of branded and generic transdermal products available to patients in markets around the world, including the U.S., Canada, Europe, Japan, New Zealand and Australia.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of approximately 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com


'/>"/>
SOURCE Mylan Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Acquisition of Agila Receives Approval from Indias Foreign Investment Promotion Board and Cabinet Committee on Economic Affairs
2. Mylan Confirms Approval of sANDA for Bupropion Hydrochloride Extended-Release Tablets USP (XL), 300 mg
3. Mylan Reports a 13% Increase in Second Quarter 2013 Adjusted Diluted EPS to $0.68
4. Third Circuit Rules in Mylans Favor Regarding Paroxetine Hydrochloride Extended-Release Tablets, Sending Mylans Breach of Contract Claim Against GSK to Trial
5. Mylan to Host Investor Day on Aug. 1, 2013 in New York City
6. Roger Graham Named President of Mylan Specialty
7. Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign
8. Mylan to Speak at the Goldman Sachs 34th Annual Global Healthcare Conference
9. New Breakthroughs Allow Companies to Expand their Reach - Research Report on Perrigo, Auxilium, Actavis, Mylan, and Salix
10. Mylan Specialty L.P. Announces Partnership with Baseball Teams Across Country to Raise Awareness of Potentially Life-Threatening Allergies
11. Presenting Sponsor Mylan Specialty L.P. Calls on Communities Nationwide to Join The Food Allergy Research & Education (FARE) Walk for Food Allergy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... IRIDEX Corporation (NASDAQ: IRIX ) today ... common stock, $0.01 par value (the "Offering" with such shares ... final terms of the Offering will depend on market and ... be no assurance as to whether or when the Offering ... net proceeds it will receive from this offering for working ...
(Date:12/8/2016)... LONDON , Dec. 8, 2016 Australia ... GlobalData,s new report, "Australia Ophthalmic Lasers Market Outlook to ... Lasers market. The report provides value, in millions of ... within market segements - Excimer Lasers, Femtosecond Lasers and ... and distribution shares data for each of these market ...
(Date:12/8/2016)... , Dec. 8, 2016 Australia ... Summary GlobalData,s new report, "Australia Glaucoma Surgery ... data on the Australia Glaucoma Surgery Devices market. ... dollars, volume (in units) and average prices (USD) ... The report also provides company shares and distribution ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... The ... beginning January 1, 2017. The name change aligns the entire company with ... improving health care quality. , “We are very proud of the achievements associated ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Florida Hospital Tampa ... Hyperbaric Medical Society (UHMS), the leading authority in hyperbaric medicine. This accreditation identifies ... few hospitals and facilities have earned this distinction. This is the second time ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... (WCRI) officially opened registration today for its 33rd Annual Issues & Research ... . , The theme of the conference is “Persistent Challenges and New Opportunities: ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported ... , “This was our first franchise-wide Quack Gives Back initiative, and ...
(Date:12/8/2016)... ... December 08, 2016 , ... ZyDoc , a New ... Conventional Data Capture Methods for Input to Electronic Health Records: A Comparative Usability ... the comparative usability study demonstrate that a dictation-based method (“NLP Entry”) using ZyDoc’s ...
Breaking Medicine News(10 mins):